tirzepatide · Eli Lilly
What should I know about Zepbound?
Zepbound by Eli Lilly: Weight · sleep apnea. Cost, side effects, dosing as labeled, comparisons and the latest news, all sourced.
Start hereZepbound FAQ: The Questions People Ask GoogleWhat Zepbound treats, which doses the label calls maintenance doses and which it does not, how much weight people lost in the trials, what it costs on every payment route, why the suicidality warning disappeared in 2026, and the storage and sharing rules that come with the new KwikPen.
Medications
Every Mounjaro and Zepbound Dose, Pen and VialTirzepatide now comes in four different devices across two brands and six strengths each. This is the complete catalog: what every dose looks like, the NDC numbers, how many doses each device holds, why the multi-dose versions use a different formulation, and how long each one lasts outside the refrigerator.Mounjaro vs Zepbound: What's the Difference?Mounjaro and Zepbound contain exactly the same drug, tirzepatide, made by the same company. What separates them is the FDA-approved use printed on the box, the devices each brand comes in, and the price you actually pay. Here is the full comparison, straight from the two labels.Wegovy vs Zepbound: Which Weight-Loss Shot Does What?Wegovy and Zepbound are the two leading FDA-approved weekly injections for weight management - they use different molecules, carry different extra indications, come in different devices and are priced very differently.Zepbound for Sleep Apnea: What the Approval MeansIn December 2024 Zepbound became the first prescription medicine ever approved for obstructive sleep apnea. This explains exactly who the approval covers, what the trials showed, why the label uses higher maintenance doses than it does for weight, and the one sentence in the label that everyone hoping to ditch their CPAP should read.Zepbound Vials Explained: LillyDirect, Prices and How They WorkZepbound single-dose vials are the cheapest way to buy brand-name tirzepatide in the United States, but they only exist inside one channel and the price depends on a 45-day refill rule most people miss. Here is how the vials work, what they cost, how the price got here, and what you have to buy separately.
How-to guides
At the Pharmacy Counter: Savings Cards, NDCs and Mail-Order for GLP-1sA savings card is a second insurance claim, not a coupon. Here is the processing code your pharmacist actually needs, how to read the NDC to confirm you got the right dose and device, and how the two manufacturer mail-order channels work.How to Dispose of GLP-1 Needles and Pens (and What Your State Allows)FDA's rule is two steps. Your state's rule is the one that decides what happens to the full container, and four states do not let it go in household trash at all. Here is the whole process, plus the free container programs most people do not know exist.How to Inject Zepbound: What the Instructions for Use Say for All Four DevicesZepbound comes as a single-dose pen, a single-dose vial, a multi-dose vial and a KwikPen. Each has its own FDA-approved Instructions for Use, and only one of them has to be primed before every dose. Here is what each document actually says.How to Store GLP-1 Pens: The Full Table, Plus Travel and HeatThere are at least seven different out-of-fridge windows across the GLP-1 products sold in the US, ranging from 21 days to 56 days, and two products that never need a fridge at all. Here is every rule, from the labels, in one place.Missed a Dose of Ozempic, Wegovy, Mounjaro or Zepbound? What the Labels SayEvery GLP-1 has a different missed-dose rule, and two of them are written backward from each other. Here is what each FDA-approved label actually says, for nine drugs, in one table.Zepbound Vial Dosing: The Units and Syringe GuideZepbound vials are dosed by volume, not by units, and the two vial types use different volumes. Here is what the label says about syringes, what 0.5 mL and 0.6 mL look like on a U-100 syringe, and why the milligram numbers on the carton are not the number you draw.
Results & daily life
Best and Worst Foods on GLP-1s, According to Dietitian GuidanceWhat registered dietitians and clinical-nutrition reviews say about which foods work and which cause trouble on semaglutide and tirzepatide — plus what the research actually shows about food aversions and taste changes.Daily Life on a GLP-1: Work, Travel, Tracking and the Stuff Nobody Warns You AboutThe practical side of living on semaglutide or tirzepatide: dose day and work, travel and storage rules from the labels, tracking apps and what the research says about them, non-scale victories, stigma at work, and the daily-life questions nobody has studied yet.Exercise on GLP-1s: What the Evidence Actually ShowsStrength training and cardio while taking semaglutide or tirzepatide: what randomized trials, meta-analyses and society guidance say about muscle, results, and what happens after the drug stops — plus an honest map of what has never been tested.GLP-1 Friendly Meal Plan: The Principles Behind ItWhat published clinical-nutrition guidance actually says about building meals on semaglutide or tirzepatide — the protein, fluid and fiber numbers, meal size and timing, what to do on bad days, and what the 'GLP-1 friendly' label on a package does and does not mean.GLP-1 Plateau: Why Weight Loss Stalls and What the Research SaysPlateaus on semaglutide and tirzepatide are expected, measurable and well described in the trial data. Here is how researchers define a plateau, when it typically arrives, why it happens, and what the studies say about what comes next.How Fast Does Zepbound Work? What the Trial Curves ShowA month-by-month look at tirzepatide's weight-loss curve from SURMOUNT-1 and the FDA label — when the dose is reached, when most of the loss happens, when people plateau, and what happens to late responders.How Much Protein on a GLP-1? What Dietitians and the Research SayProtein targets on semaglutide and tirzepatide, where the numbers come from, why per-kilogram advice is confusing, what the body-composition data actually shows, and why protein alone will not do the job.
Pipeline
CagriSema: What to Know While It Sits at the FDACagriSema is Novo Nordisk's combination of semaglutide and the amylin drug cagrilintide. It has been under FDA review since December 2025. Here is what the REDEFINE trials found, why the head-to-head against Zepbound mattered, and what a decision would actually mean for you.Lilly vs. Novo Nordisk: The Obesity Drug War, ExplainedHow Eli Lilly overtook Novo Nordisk in the US weight-loss market, where Novo is still winning, and what the rivalry means for what you pay and what you can get.Retatrutide: What to Know and When You Could Actually Get ItRetatrutide produced the largest average weight loss ever reported in a pivotal obesity trial, but it is still investigational. Here is where it stands, what the numbers really say, when Eli Lilly plans to file with the FDA, and how people are getting access legally today.
Culture
Celebrities on Mounjaro and Zepbound: A Sourced ListA list of public figures who have said, in their own words, that they used tirzepatide - either Mounjaro or Zepbound - with the date, the outlet and what they actually said, plus a clear line between unpaid disclosures and paid brand partnerships.How Many Americans Take Zepbound or Mounjaro: The NumbersNo survey publishes a clean count of US Zepbound or Mounjaro users, so this guide assembles what is actually measured - prescriptions, revenue, market share and poll numbers - and explains what each one does and does not tell you.How Zepbound Overtook WegovyZepbound launched two years after Wegovy and passed it in new prescriptions within about three months. This is the sourced story of how tirzepatide took the US weight-loss market, told through prescription data, a head-to-head trial, a cash-price war, one enormous insurance decision and a lawsuit.
Stopping & switching
Coming Off Compounded Semaglutide: How the Transition WorksCompounded semaglutide is winding down. Moving to an FDA-approved product means a new prescription, a dose your prescriber has to map by hand, and no overlap between products. Here is how the transition works and what to bring to the appointment.Do You Have to Take Wegovy Forever?The label sets no stop date and obesity societies now strongly recommend continuing during maintenance - but two 2026 trials changed the question from whether to stop to whether you can use less.GLP-1 Maintenance Dose: What the Research SaysTwo 2026 randomized trials finally tested whether you can hold weight loss on less drug. Here is what they found, what the labels allow, and why 'microdosing' is still a marketing term rather than a protocol.Switching From Wegovy to Zepbound: What to KnowThere is no FDA-approved dose conversion between semaglutide and tirzepatide. Here is what the labels actually say, what published switching data shows, and the questions worth asking before your first Zepbound dose.What Happens When You Stop Taking a GLP-1: The EvidenceRandomized trials, real-world databases and meta-analyses now give a fairly clear picture of what happens to weight, blood sugar, blood pressure and body composition after a GLP-1 stops - and where the numbers disagree.
Compounded & telehealth
Compounded Tirzepatide vs Zepbound: Cost and Differences in 2026Compounded tirzepatide used to cost a fraction of Zepbound. In 2026 the gap has largely closed. Here's an honest side-by-side on price, oversight, evidence, device and legal standing — and the hidden fees that make advertised numbers misleading.Compounded Tirzepatide: What It Is and Whether It's Legal in 2026Compounded tirzepatide is a pharmacy-mixed version of the active ingredient in Mounjaro and Zepbound. It is not FDA-approved. Since the shortage ended, only narrow patient-specific compounding remains lawful — here's what changed, what's still allowed, and what to ask.How to Spot Fake Mounjaro or ZepboundCounterfeit tirzepatide is sold on social media, through offshore websites and at some med-spas. Here is what a genuine Mounjaro or Zepbound pen looks like, what regulators and Eli Lilly have found inside fakes, and the checks you can run before you inject anything.Where to Get Zepbound Online: How the Options Compare in 2026Zepbound's medication price is set by Eli Lilly and is the same through most online platforms. What differs is the platform fee, the insurance help and the device. Here's how LillyDirect, Ro, Sesame, Hims, Amazon, GoodRx and the rest actually compare.
Getting started
Do I Qualify for Wegovy, Zepbound or Another GLP-1?A plain-English walk through who each FDA-approved GLP-1 is actually labeled for, where the BMI 30 and BMI 27 rules come from, what counts as a weight-related condition, and why your insurance plan may use stricter rules than the FDA label.How to Get a GLP-1 Prescription: Every Legitimate RouteThe six real ways to get an FDA-approved GLP-1 prescription in the US, what each one costs in time and money, what the FDA says about the sellers you should avoid, and how to verify anyone before you hand over a card number.Questions to Ask Your Doctor About GLP-1 MedicationThirty-one questions worth asking before and after you start a GLP-1, each one tied to something a specific FDA label, guideline recommendation or federal rule actually says, plus what a good answer sounds like.What to Expect Your First Month on a GLP-1Week by week through the starting dose, why it is deliberately too low to be a treatment dose, the side effect rates recorded in trials, the missed-dose rules that differ by product, and what the labels say should prompt a call to your clinician.Which GLP-1 Is Right for Me? How Doctors DecideWhat the guidelines actually say about choosing between semaglutide, tirzepatide, orforglipron and liraglutide, plus the seven practical factors that usually settle it, including the one clinicians rarely say out loud.
Cost & insurance
Does Insurance Cover Zepbound? How to Check and How to AppealSixty percent of commercially insured Americans have no coverage for Zepbound, and roughly nine in ten of those who do face prior authorization or step therapy. Here is exactly how to check your own plan, what the big three pharmacy benefit managers say in 2026, and the appeal sequence that actually works when you are denied.Does Medicare Cover Zepbound or Mounjaro?Medicare cannot cover a drug used only for weight loss, but there are now three separate doors to tirzepatide: Part D covers Mounjaro for type 2 diabetes, Part D can cover Zepbound for obstructive sleep apnea, and the Medicare GLP-1 Bridge covers the Zepbound KwikPen at $50 a month through 2027. Here is which door you qualify for.How Much Does Zepbound Cost Without Insurance in 2026?Zepbound's list price is about $1,086 a month, but almost nobody pays it. Eli Lilly sells it directly for $299 to $449 by dose, the same price for the vial or the KwikPen, and that price is now available at most pharmacies. Here is every cash route, what each one really costs, and the 45-day rule that can add $250 a month.The Cheapest Way to Get Tirzepatide Legally in 2026Seven legal routes to tirzepatide, ranked by what they actually cost in 2026, with the catch attached to each. The cheapest legitimate route for most cash payers is Eli Lilly's own self-pay channel at $299 to $449 a month, and the biggest hidden cost is not the pharmacy you choose but the 45-day refill clock.The Zepbound Savings Card ExplainedThere are three different Lilly offers people call 'the Zepbound coupon,' and they land on $25, $499 or $299 depending on your insurance and which device your prescription names. Here is which one applies to you, the caps that decide whether you actually reach $25, and who is shut out.
Side effects & safety
Does Zepbound Cause Hair Loss? What the Label and the Studies Actually SayHair loss is a listed Zepbound side effect with real numbers behind it. Here is how common it was in the trials, why it affected women far more than men, what the newest population studies found, and why researchers think rapid weight loss is doing most of the work.Mounjaro and Zepbound Lawsuits: What Is Actually Alleged, and Where the Cases StandA plain-English account of the tirzepatide litigation: which injuries are alleged, which courts are handling it, what Eli Lilly argues in its own filings, and what has and has not been decided as of September 2026.Mounjaro Side Effects: What the FDA Label Actually ReportsThe full list of Mounjaro (tirzepatide) side effects from the FDA prescribing information, with trial percentages, the ten warnings, what the four-year SURPASS-CVOT trial found, and how the Mounjaro label differs from Zepbound's.Tirzepatide vs Semaglutide Side Effects: What the Head-to-Head Evidence ShowsA direct comparison of Zepbound and Mounjaro against Wegovy and Ozempic on side effects, using the one randomized head-to-head trial, the best observational study, and the differences written into the two labels.Zepbound and Alcohol: What the Label Says, and Why People Report Drinking LessThere is no alcohol interaction on the Zepbound or Mounjaro label. The real concerns are indirect — dehydration, low blood sugar with insulin, and pancreatitis risk — and separately, a growing body of research finds people on tirzepatide drink less.Zepbound Side Effects: The Complete List and How Common Each One IsEvery Zepbound (tirzepatide) side effect that appears in the FDA prescribing information, with the actual trial percentage next to each one, plus the warnings, the contraindications and the things that are reported but not on the label.
Companies
Eli Lilly's Pipeline: What Comes After ZepboundRetatrutide, eloralintide, bimagrumab and a $25 billion buying spree. What Eli Lilly is working on next, how far along each of it is, and why you should not try to buy any of it online.Who Makes Mounjaro and Zepbound? Eli Lilly, ExplainedEli Lilly and Company makes both drugs, and they contain the same medicine. Here is who the company is, where the drugs are made, how LillyDirect works, and why the same molecule carries two different brand names.
Foundayo
Foundayo vs. the Wegovy Pill: How the Two GLP-1 Tablets CompareFoundayo (orforglipron) and the Wegovy pill (oral semaglutide 25 mg) are the only two GLP-1 tablets approved in the US for weight management. They differ on how you take them, how much weight they produced in trials, what else they are approved to do, and what they cost.How Much Does Foundayo Cost in 2026? Self-Pay, Insurance and MedicareFoundayo (orforglipron) has no single price. Lilly charges by dose, from $149 to $349 a month for self-pay, about $25 a month with commercial insurance that covers it, and $50 a month through the Medicare GLP-1 Bridge. Here is every published price, where each one applies, and the traps people keep hitting.
Specific groups
GLP-1 Drugs and Men's Health: Testosterone, Sex, Muscle and ResultsMen lose less percentage weight than women on the same dose, their testosterone tends to rise as they lose weight, the erectile function evidence points in two directions at once, and the muscle question is real. Here is what the 2025-2026 research actually found.GLP-1s After Bariatric Surgery: What the Evidence Says in 2026Weight coming back after gastric sleeve or bypass is common, and adding semaglutide or tirzepatide is now one of the most-studied responses to it. A 2026 randomized trial and a 208,000-patient US cohort finally give real numbers - here is what they found, and what nobody has tested yet.Who Should Not Take GLP-1 Drugs, According to the LabelsThe FDA labels for Wegovy, Ozempic, Zepbound and Mounjaro list exactly two absolute contraindications each. Everything else - pancreatitis, gallbladder disease, gastroparesis, pregnancy, surgery, eye disease - sits in warnings, 'not recommended' statements, and gaps where nobody has studied the question at all. Here is the actual list.
Market & policy
GLP-1 Prescriptions in the US: The Numbers by QuarterHow many GLP-1 prescriptions Americans actually fill, quarter by quarter and week by week, plus the revenue those prescriptions generate for Novo Nordisk and Eli Lilly, and why the published numbers disagree with each other.Where Americans Actually Buy GLP-1s NowThe GLP-1 prescription moved out of the insurance benefit and into the checkout line. Here is how the cash-pay channel works, what each retailer and telehealth platform charges, and what the shift means for your pharmacy record.Where GLP-1 Drugs Are Made in the USA state-by-state map of the US plants making semaglutide and tirzepatide, the tens of billions being spent to build more, the jobs those plants create, and why tariffs and drug pricing deals drove the whole build-out.
Insurance navigation
GLP-1 Prior Authorization: What Insurers Actually RequireWhat the published prior authorization criteria from UnitedHealthcare, CVS Caremark, Aetna, Cigna, Express Scripts and BCBS FEP actually say about BMI, comorbidities, lifestyle programs, step therapy, quantity limits and renewals — with the documents quoted and linked.How to Appeal a GLP-1 DenialHow to read a denial letter, tell an exclusion from a medical necessity denial, work through internal appeals, and use your right to an independent external review — with deadlines, required notice contents, and what the data says about your odds.How to Get Wegovy or Zepbound Covered by InsuranceA step-by-step process for finding out whether your plan covers a GLP-1 for weight loss, what it will require, and what to do at each fork in the road — written for the person holding the insurance card, not the prescription pad.HSA and FSA for GLP-1 DrugsWhether you can pay for Wegovy, Zepbound, Ozempic or a compounded GLP-1 with tax-free HSA or FSA money, when a letter of medical necessity is needed, what the tax deduction really requires, and how to work out whether to run a fill through insurance or pay cash.Medicaid Coverage of GLP-1s by StateWhich state Medicaid programs cover GLP-1s for obesity, which coverage is required in every state no matter what, what changed in 2025 and 2026, and how to check your own state's rules — plus how ACA Marketplace coverage compares.Medicare GLP-1 Bridge: How It WorksThe step-by-step mechanics of Medicare's GLP-1 Bridge demonstration: who qualifies, which products and devices are covered, how the prescription and prior authorization must be sequenced, what the $50 copay does and does not count toward, and why there is no appeal.Novo Nordisk and Lilly Patient Assistance Programs ExplainedWho actually qualifies for the Novo Nordisk Patient Assistance Program and the Lilly Cares Foundation, what the savings cards really cap out at, why a $25 card can turn into a $500 bill in month six, and how copay accumulators and alternative funding programs change the picture.
How they work
How Does Zepbound Work? GIP and GLP-1 ExplainedZepbound is tirzepatide, the same molecule as Mounjaro, approved for weight management and sleep apnea. It activates two gut hormone receptors - GIP and GLP-1 - and this guide explains what each one does to appetite, fat tissue and the brain.How Long Does Tirzepatide Stay in Your System?Tirzepatide has a half-life of about five days, so after a last dose it takes roughly three and a half to four weeks to clear. Here is what the label says about half-life, steady state, missed doses, washout and what happens when you stop.Semaglutide vs Tirzepatide: How the Two Drugs Actually DifferSemaglutide hits one receptor, tirzepatide hits two - and in the only head-to-head trial, tirzepatide produced more weight loss, though the two molecules differ in more ways than a single number captures.Tirzepatide and Birth Control: What the Label Actually SaysMounjaro and Zepbound are the only once-weekly GLP-1-family drugs whose US labels carry a specific oral contraceptive warning. Here is the exact wording, the study numbers behind it, and how it differs from semaglutide.
Clinical trials
How Much Weight Do People Lose on Zepbound? The Numbers From Every TrialEvery published tirzepatide weight-loss figure in one place — by dose, by population, by trial, and by how it was measured — plus what the same drug does outside of a clinical trial.Semaglutide vs Tirzepatide Head to Head: What SURMOUNT-5 FoundSURMOUNT-5 is the only large randomized trial that pitted tirzepatide directly against semaglutide at obesity doses — here are the numbers, the caveats, and what the trial could not measure.SURPASS-CVOT Explained: What the Big Tirzepatide Heart Trial Actually ShowedThe 13,299-person trial that tested Mounjaro against Trulicity for heart attacks, strokes and deaths — what non-inferiority means, why the mortality number comes with a caveat, and what is still unanswered.What Happens When You Stop Taking Zepbound? What SURMOUNT-4 and SURMOUNT-MAINTAIN FoundThe two randomized trials that tested stopping tirzepatide — what people regained, how fast, and what happened to the group that lowered their dose instead of quitting.What the Clinical Trials Actually Show About TirzepatideA plain-English tour of the tirzepatide evidence base — the SURPASS diabetes trials, the SURMOUNT obesity trials, the heart and sleep apnea studies, what the numbers were, and where the evidence still runs out.Zepbound Results Timeline: What the Trials Show Week by WeekA week-by-week walk through what happened to trial participants on tirzepatide — from the first low dose through escalation, the steep middle stretch, the plateau, and what the three-year data shows.
FDA & regulation
Is Compounded Tirzepatide Legal in 2026? What the FDA Actually SaysLarge-scale compounding of tirzepatide copies lost its legal basis on February 18, 2025 for pharmacies and March 19, 2025 for outsourcing facilities. A narrow path remains for small-volume, patient-specific compounding, and the FDA has spelled out where the line sits.Is Tirzepatide Still in Shortage? The Full Mounjaro and Zepbound TimelineTirzepatide came off the FDA drug shortage list on October 2, 2024, was put back under review after a lawsuit, and was declared resolved again on December 19, 2024. It has stayed off the list ever since, and courts have upheld that decision twice.The Complete FDA Approval History of Tirzepatide (Mounjaro and Zepbound)Tirzepatide has two US brand names, two application numbers and six separate approved uses. Here is every FDA decision from the May 13, 2022 Mounjaro approval through the August 2026 cardiovascular indication, with the supplement numbers and trial names behind each one.Tirzepatide Approvals Around the World: Mounjaro and Zepbound by CountryTirzepatide is approved in the US, EU, UK, Canada, Japan, China, Australia, India and beyond, but the brand names and the approved uses differ by country. In the UK and EU, Mounjaro is also the weight-loss brand, which trips up a lot of American readers.
Beyond weight loss
Microdosing Zepbound: What's Actually KnownNo randomized trial has ever tested intentional microdosing of tirzepatide. But 2026 brought three things that change the conversation: a US multi-dose pen, a randomized trial of dose reduction, and an FDA proposal to shut down compounded supply.Tirzepatide and Heart Failure: The SUMMIT Trial ExplainedSUMMIT was the first trial to show a drug could change the course of obesity-related heart failure with preserved ejection fraction. It cut heart failure events by 38 percent. It still did not produce an approved indication in the United States or Europe, and the reasons why are worth understanding.Tirzepatide for PCOS: What the Evidence Actually ShowsTirzepatide is not approved for polycystic ovary syndrome anywhere. One small randomized trial, a large real-world cohort and a newly launched phase 4 trial are the whole evidence base — and they point in a specific, limited direction.What Else Can Tirzepatide Treat? Beyond Weight Loss and DiabetesTirzepatide has exactly four FDA-approved uses in the United States, split across two brand names. Everything else you have read about it — heart failure, fatty liver, PCOS, addiction, dementia — sits somewhere on a long ladder between a strong trial and a hopeful database study.Zepbound for Sleep Apnea: What the Evidence Actually ShowsZepbound is the first and only medication the FDA has approved for obstructive sleep apnea. The trial behind it is strong, the effect is large, and the two questions nobody can answer yet are whether it replaces CPAP and what happens if you stop.
FAQ
Mounjaro: 50 Questions People Ask GoogleThe fifty questions Americans actually type into Google about Mounjaro, answered from the FDA label, Eli Lilly's own pricing pages and the 2026 approvals — including why US and UK answers disagree, what the new heart indication does and does not say, and what a month really costs on every payment route.Zepbound: 50 Questions People Ask GoogleThe fifty questions Americans actually type into Google about Zepbound, answered from the FDA label, Eli Lilly's own pricing pages and the 2026 approvals — including the sleep apnea indication no other drug has, the three savings offers people confuse, the 45-day refill rule that can add $250 a month, and what the KwikPen changed.
Alternatives
News
The Biggest Eli Lilly GLP-1 Stories of 2026 So FarTirzepatide, the Foundayo pill launch, retatrutide's record weight loss, a heart indication for Mounjaro and a lawsuit between the two biggest names in obesity — everything that has moved Eli Lilly's GLP-1 business from January to mid-September 2026.The Biggest Zepbound and Mounjaro Stories of 2025The twelve developments that reshaped tirzepatide in 2025, from the first Medicare opening and the CVS formulary shock to the head-to-head win over Wegovy, a 170% UK price rise, and Eli Lilly becoming the first trillion-dollar drugmaker.Tirzepatide: A Year-by-Year History of Mounjaro and ZepboundHow one molecule went from an experimental diabetes shot in 2022 to two American brands, four approved uses, the world's best-selling medicine, and the drug every new obesity treatment is measured against.
Recent Zepbound news
Full timeline- Research
Label check: what the current Zepbound prescribing information actually says about dosing
- Prices
Status check: the Zepbound formulary class action against CVS Caremark remains live as restoration nears
- Prices
Aetna posts a Standard Control Choice formulary addition for Zepbound effective October 1
- Compounding
Branded tirzepatide self-pay prices sit far below the shortage-era gap
- Culture
r/Zepbound passes 233,000 members, r/Mounjaro passes 204,000
- Research
Comparative review: tirzepatide wins on weight, not on tolerability
- Research
Peer-reviewed Zepbound cost-offset numbers published in Diabetes, Obesity and Metabolism
- Business
Lilly says international incretin growth ran at 136% and flags generic supply constraints in Canada